FDA 483 - Biogen U.S. Corporation - August 19, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Biogen U.S. Corporation in Research Triangle Park, NC, underwent an FDA inspection of its drug manufacturing facility. The inspection identified a critical lapse in data integrity and control, specifically the absence of procedures to review calculations within an un-validated Excel spreadsheet. This spreadsheet was used for establishing Assay Acceptance Criteria for Tofersen drug substance and drug product, indicating a failure to ensure accuracy in related data systems.
ID · 4b8c485a-80e3-4311-999d-a8448d1caed5